Comparing Methotrexate and Azathioprine for Chronic Actinic Dermatitis
Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis
This study is testing whether methotrexate or azathioprine is a better and safer treatment for people with Chronic Actinic Dermatitis while making sure everyone follows sun protection guidelines.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 88 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Pak Emirates Military Hospital Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Rawalpindi, Punjab) |
| Trial ID | NCT06476366 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy and safety of methotrexate and azathioprine in treating patients with Chronic Actinic Dermatitis (CAD). Participants will be randomly assigned to receive either methotrexate or azathioprine, with both groups advised on strict sun protection measures. The study aims to determine the safety and effectiveness of these treatments and whether one is superior to the other. By exploring these cost-effective alternatives, the trial seeks to enhance treatment options for CAD patients.
Who should consider this trial
Good fit: Ideal candidates include newly diagnosed patients or those with an established diagnosis of Chronic Actinic Dermatitis.
Not a fit: Patients with coexisting conditions requiring immunosuppressants or those with neuropsychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide safer and more effective treatment options for patients suffering from Chronic Actinic Dermatitis.
How similar studies have performed: While the use of methotrexate and azathioprine has been successful in other dermatoses, this specific comparison in CAD is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All newly diagnosed as well as patients with an established diagnosis of CAD presenting to the outpatient department or the emergency department of PEMH or CMH will be included in the study. Exclusion Criteria: * Patients with coexisting conditions requiring immunosuppressants will be excluded from the study. Patients with dementia or any other neuropsychiatric disorder will also be excluded.
Where this trial is running
Rawalpindi, Punjab
- Pak Emirates Military Hospital — Rawalpindi, Punjab, Pakistan (Recruiting)
Study contacts
- Principal investigator: Ahsan Tameez-ud-din — Pak Emirates Military Hospital
- Study coordinator: Ahsan Tameez-ud-din, MBBS
- Email: ahsantameezuddinmalik@gmail.com
- Phone: +923315166726
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.